Regulation of banks

This subtopic contains the following documents:

Practice Notes

  1. The EU’s Single Rulebook—in June 2012, the European Council proposed the establishment of the European Banking Union as part of a longer term vision for further economic and monetary integration for all EU Member States in the eurozone (an economic and monetary union of the EU Member States). A core element of the Banking Union consisted of the development of a Single Supervisory Mechanism (SSM), establishing the European Central Bank as the overarching prudential supervisor of significant eurozone banks. This Practice Note looks at the Single Rulebook, which is used under the SSM with the intention of achieving a uniform prudential regulatory framework throughout the EU financial sector, creating greater consistency, transparency and efficiency.

  2. The EU’s Single Supervisory Mechanism—the European Banking Union is underpinned by a single regulatory rulebook for financial services, which is intended to promote the integration of banking supervision within the EU. Central to the European Banking Union is the Single Supervisory Mechanism (SSM) (established by Council Regulation (EU) 1024/2013 (the SSM Regulation)). The SSM is designed to ensure

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents